Wedbush Forecasts Increased Earnings for Avalo Therapeutics

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – Investment analysts at Wedbush upped their Q1 2025 EPS estimates for Avalo Therapeutics in a research report issued on Thursday, March 20th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of $0.63 per share for the quarter, up from their prior estimate of $0.55. Wedbush has a “Outperform” rating and a $18.00 price objective on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($19.07) per share.

A number of other equities analysts also recently weighed in on AVTX. Piper Sandler began coverage on shares of Avalo Therapeutics in a research note on Friday, February 28th. They issued an “overweight” rating and a $48.00 price target on the stock. HC Wainwright reaffirmed a “neutral” rating on shares of Avalo Therapeutics in a research note on Thursday. Finally, BTIG Research assumed coverage on shares of Avalo Therapeutics in a research note on Thursday, December 19th. They set a “buy” rating and a $40.00 price target on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.33.

Avalo Therapeutics Stock Performance

Shares of Avalo Therapeutics stock opened at $7.66 on Friday. Avalo Therapeutics has a one year low of $4.60 and a one year high of $34.46. The firm has a fifty day moving average of $7.45 and a two-hundred day moving average of $9.12.

Institutional Investors Weigh In On Avalo Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of AVTX. Tower Research Capital LLC TRC grew its holdings in shares of Avalo Therapeutics by 998.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after purchasing an additional 3,754 shares in the last quarter. Marshall Wace LLP acquired a new position in Avalo Therapeutics in the fourth quarter valued at about $114,000. Walleye Capital LLC acquired a new position in Avalo Therapeutics during the 4th quarter worth about $145,000. Northern Trust Corp acquired a new position in Avalo Therapeutics during the 4th quarter worth about $168,000. Finally, Bank of Montreal Can acquired a new position in Avalo Therapeutics during the 4th quarter worth about $446,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.